Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Filter Results By

Filter Applied. Clear All
Reset All Filters
Scholar

Eugene C. Tarne

Senior Analyst

Eugene C. Tarne is a senior analyst with the Charlotte Lozier Institute. He is also the president of Tarne Communications Inc., a communications and issue advocacy company he founded in 1999. For more than 25 years, beginning in 1989, Mr. Tarne served as a communications and media relations consultant to the United States Conference of Catholic Bishops Secretariat for Pro-Life Activities. In this capacity, he works closely with the Pro-Life Secretariat to develop messages, promote issues and legislation, develop new programs and materials and implement communications strategies designed to educate the public and promote pro-life issues in the public square. These issues include abortion, assisted suicide and euthanasia, and bioethical issues, especially cloning and stem cell research. In 1996, Mr. Tarne helped found the Physicians Ad Hoc Coalition for Truth (PHACT), an organization of doctors and other medical professionals formed to bring the medical facts to bear on the partial-birth abortion debate. Mr. Tarne also served as Communications Director for Do No Harm: The Coalition of Americans for Research Ethics, a coalition of scientists, researchers, bioethicists, medical, academic and other professionals, patient advocates, and concerned individuals, established in 1999, to promote the ethical pursuit of stem cell research and regenerative medicine in general, and to provide accurate information on such research. Mr. Tarne graduated from Georgetown University in 1977 with a B.A. in Theology. He received his M.A. in History of Religions from The George Washington University in 1979. He was offered scholarships to Harvard, the University of Chicago and the University of Pennsylvania to pursue a Ph.D. in South Asian Studies. He attended the University of Chicago and later the University of Pennsylvania, where he completed his Ph.D. studies, except for dissertation.

Research Authored

Fetal Tissue, Stem Cells & Bioethics

Next Station Stop: The Embryo Farm?

For decades, proponents of destructive embryo research have given at least lip service recognition to the serious ethical concerns inherent to such research. Thus, for example, although the 1999 report from then-President Clinton’s National Bioethics Advisory Commission, Ethical Issues in Human Stem Cell Research, endorsed destructive human embryonic stem cell research (hESCR) and federal funding for it, it nonetheless recognized that the ethical concerns raised by this research were real and that “many would likely agree: the embryo merits respect as a form of human life.”

featured-image
Fetal Tissue, Stem Cells & Bioethics

Fox Foundation Funding Patterns Favor Ethical Approaches

But while the Fox Foundation, like CIRM, may have started out emphasizing support for hESCR, that support, also like CIRM’s, has waned over the years. According to its website, the MJFF has awarded 1,350 research grants since its founding in 2000.  Of that total number, just 66 grants went to research using stem cells.

featured-image
Fetal Tissue, Stem Cells & Bioethics

California Stem Cell Clinical Trials Show Ethical Alternatives Are Most Promising

featured-image
Fetal Tissue, Stem Cells & Bioethics

Time to End Embryo-Destroying Stem Cell Research

Will induced pluripotent stem cells (iPSCs) finally replace human embryonic stem cells (hESCs) in the field of regenerative medical research? Results of a recent study published in Nature Biotechnology argue that they should.

featured-image
Fetal Tissue, Stem Cells & Bioethics

Stem Cell Awareness Day: Major Research Center’s Quest for Cures Uses Ethical Sources Only

featured-image
Fetal Tissue, Stem Cells & Bioethics

Clarifying a White House Letter on Stem Cell Research

Early in 2013, Gavin was diagnosed with Hodgkin’s lymphoma. Gavin courageously fought back against his diagnosis. Doctors utilized stem cells to treat Gavin and this treatment, combined with Gavin’s bravery, led to victory in his battle against this cancer.

featured-image
Fetal Tissue, Stem Cells & Bioethics

Stem Cell Research: Predictions, Predilections and Progress

featured-image
Fetal Tissue, Stem Cells & Bioethics

Ethical Adult Stem Cell Treatments Result in “Profound Improvement” for MS Patients

British media are reporting a significant development in the use of ethical, non-embryonic stem cells to treat patients with multiple sclerosis (MS) and, perhaps, other auto-immune diseases.

featured-image
Fetal Tissue, Stem Cells & Bioethics

The Continuing Promise of Non-Embryonic Stem Cells

featured-image
Fetal Tissue, Stem Cells & Bioethics

Scientific Advances in Stem Cell Research Continue to Make Use of Embryos Outdated and Unnecessary

Diabetes has long been one of the main diseases for which human embryonic stem cell (embryo-destroying) research, or hESCR, was claimed to hold the greatest promise of curing. But for well over a decade now, ethically contentious human embryonic stem cell research (hESCR) has notably failed to live up to all its hype, with promises of miracle cures within “five to 10 years” remaining unfulfilled.